Approval Summary : Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

@inproceedings{Kazandjian2016ApprovalS,
  title={Approval Summary : Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy},
  author={Dickran Kazandjian and Daniel L. Suzman and Gideon Michael Blumenthal and Sirisha Mushti and Meredith Libeg and Patricia Keegan},
  year={2016}
}
On October 9, 2015, the U.S. Food and Drug Administration expanded the nivolumab metastatic non-small cell lung cancer (NSCLC) indication to include patients with nonsquamous NSCLCaftera3.25-monthreviewtimeline.Approvalwasbased ondemonstrationof an improvement inoverall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients withmetastatic nonsquamous NSCLC with progression on or after platinumbased chemotherapy. The CheckMate… CONTINUE READING